Putting worker safety and product quality at the forefront of the HPAPI Industry - Highly Potent Active Pharmaceutical Ingredients 2019

Top Quote Conference focusing on Tthe future of injectable drug delivery - regulations, connected devices and the push for patient centricity. End Quote
  • (1888PressRelease) January 19, 2019 - SMi reports: As the 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference returns to London in May 2019, industry professionals are set to discuss overcoming the latest challenges of the HPAPI industry.

    The HPAPI global market has developed rapidly in the past year and is expected to continue to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.

    The event will explore current market trends, challenges of correctly assessing hazard, the use of innovative containment solutions to minimise risk and advanced manufacturing processes.

    PROGRAMME HIGHLIGHTS:
    Interactive debate on the importance of control matrices and algorithms to ensure confidence in containment
    Mastering the fundamentals of ADC development with Regeneron
    Analysing the principals of containment designs with AstraZeneca
    Using case studies by Gedeon Richter to optimise quality risk management
    Practical elements in rolling out HPAPI projects
    OH/containment strategy and NPI at AbbVie

    Download the event brochure to view the full two-day agenda

    http://www.highlypotentapi.com/pr2

    High profile speakers include:
    Conference Chair:
    Justin Mason-Home, Director, HPAPI Project Services Limited

    Featured Speakers:
    Dr Olindo Lazzaro, Director, Global EHS Technical Operations, AbbVie
    Dr Thomas Adam, Head of Global Quality Assurance Chemical APIs, Bayer
    Mr Peter Marshall, Associate Engineering Director, AstraZeneca
    Dr Thomas Nittoli, Director, Regeneron
    Mr Nigel Saunders, SME Containment, GSK
    Dr Jack Brown, Senior Principal Scientist, Boehringer Ingelheim

    Register before the 31st January 2019 to save 400 on your booking

    http://www.highlypotentapi.com/pr1.

    Highly Potent Active Pharmaceutical Ingredients 2019
    Conference: 13th and 14th May 2019
    Post-conference workshop: 15th May 2019
    Holiday Inn Kensingston Forum, London, UK

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information